A protein called LIGHT, a member of the tumor necrosis factor family, is a potential target for inhibiting the airway remodeling seen in patients with asthma, report investigators in the United States and Germany (Doherty TA et al. Nat Med. doi:10.1038/nm.2356 [published online ahead of print April 17, 2011])
Unresolved inflammation in the lungs of patients with chronic asthma leads to structural remodeling of the airways, including accumulation of collagen and thickening of smooth muscle. Current therapies for asthma help control symptoms and airway inflammation but they have little effect on lung remodeling.
Hampton T. Asthma Target. JAMA. 2011;305(21):2162. doi:10.1001/jama.2011.725
Customize your JAMA Network experience by selecting one or more topics from the list below.